Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Analyst Ratings
Moderate Buy
6 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRK Stock 12 Month Forecast
Average Price Target
$103.73
▲(3.32% Upside)
| Highest Price Target$139.00 | Average Price Target$103.73 | Lowest Price Target$82.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Jefferies
$138→$139
Buy
38.45%
Upside
Reiterated
11/25/25
Wells Fargo
$90→$125
Buy
24.50%
Upside
Upgraded
11/24/25
Citi
$95
Hold
-5.38%
Downside
Reiterated
11/20/25
TR | OpenAI - 4o
$98→$110
Buy
9.56%
Upside
Reiterated
11/19/25
AI Generated ArticleAI Generated Article
Berenberg Bank
$90→$95
Hold
-5.38%
Downside
Reiterated
11/19/25
Scotiabank
$105
Buy
4.58%
Upside
Reiterated
11/19/25
BMO Capital
$82
Hold
-18.33%
Downside
Reiterated
11/18/25
Bank of America Securities
$98→$105
Buy
4.58%
Upside
Reiterated
11/17/25
Merck's Strategic Acquisition and Growth Potential: Analyst Upgrades Stock Rating to 'Buy'We rate MRK as Buy on valuation. In our view, the stock is too cheap for the growth it should be able to deliver on a near- and long-term basis, but admittedly, pending Keytruda competitor datasets in 2026, and Keytruda LOE in 2029 may continue to make investors apprehensive until additional solutions come through. MRK describes the 2029+ period as more of a “hill” versus a “cliff,” and our model shows the same. before it, should help make the description more believable to more investors. We raise our PO from $98 to $105, which is a 11x (vs 10x before) multiple on our unchanged 2026 EPS, given better long-term earnings visibility. For a summary of MRK’s late-stage pipeline and catalysts, see these recent reports: in Context.
Morgan Stanley
$100
Hold
-0.40%
Downside
Reiterated
11/14/25
Hold Rating on Merck & Company: Balancing Strategic Acquisitions and Future Growth ProspectsWe view this acquisition as encouraging and consistent with the company’s prior commentary. MRK has indicated that acquisitions in the $1bn–$15bn range remains its preferred deal size and expects to be well-positioned for growth beyond the Keytruda LOE through additional transactions such as Verona (LINK) and EyeBio (LINK), alongside continued progress on its internal pipeline (see HERE).
Bernstein
$95
Hold
-5.38%
Downside
Reiterated
11/06/25
Merck & Company: Hold Rating Maintained Amid Mixed Performance and Revised GuidanceWe learned Enflonsia revenue for the first time on the call ($79M) driven by CDC stockpiling ahead of the RSV season. Gardasil stabilized in the quarter and met consensus, but ACIP one-dose vote risks remains ahead (albeit no scheduled ACIP meeting before year end). Our take: A decent performance this quarter, but nothing meaningfully changing the view on P/E multiple rerating (pipeline / M&A) or path to EPS growth beyond Keytruda patent. Post the quarter announcement, we do praise the Blackstone sac-TMT funding deal, a good option for MRK to manage spend ($700m in 2026) as they head towards pipeline expansion & Keytruda cliff.
Leerink Partners
$107
Buy
6.57%
Upside
Reiterated
10/13/25
J.P. Morgan
$120
Buy
19.52%
Upside
Reiterated
09/16/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
$138→$139
Buy
38.45%
Upside
Reiterated
11/25/25
Wells Fargo
$90→$125
Buy
24.50%
Upside
Upgraded
11/24/25
Citi
$95
Hold
-5.38%
Downside
Reiterated
11/20/25
TR | OpenAI - 4o
$98→$110
Buy
9.56%
Upside
Reiterated
11/19/25
AI Generated ArticleAI Generated Article
Berenberg Bank
$90→$95
Hold
-5.38%
Downside
Reiterated
11/19/25
Scotiabank
$105
Buy
4.58%
Upside
Reiterated
11/19/25
BMO Capital
$82
Hold
-18.33%
Downside
Reiterated
11/18/25
Bank of America Securities
$98→$105
Buy
4.58%
Upside
Reiterated
11/17/25
Merck's Strategic Acquisition and Growth Potential: Analyst Upgrades Stock Rating to 'Buy'We rate MRK as Buy on valuation. In our view, the stock is too cheap for the growth it should be able to deliver on a near- and long-term basis, but admittedly, pending Keytruda competitor datasets in 2026, and Keytruda LOE in 2029 may continue to make investors apprehensive until additional solutions come through. MRK describes the 2029+ period as more of a “hill” versus a “cliff,” and our model shows the same. before it, should help make the description more believable to more investors. We raise our PO from $98 to $105, which is a 11x (vs 10x before) multiple on our unchanged 2026 EPS, given better long-term earnings visibility. For a summary of MRK’s late-stage pipeline and catalysts, see these recent reports: in Context.
Morgan Stanley
$100
Hold
-0.40%
Downside
Reiterated
11/14/25
Hold Rating on Merck & Company: Balancing Strategic Acquisitions and Future Growth ProspectsWe view this acquisition as encouraging and consistent with the company’s prior commentary. MRK has indicated that acquisitions in the $1bn–$15bn range remains its preferred deal size and expects to be well-positioned for growth beyond the Keytruda LOE through additional transactions such as Verona (LINK) and EyeBio (LINK), alongside continued progress on its internal pipeline (see HERE).
Bernstein
$95
Hold
-5.38%
Downside
Reiterated
11/06/25
Merck & Company: Hold Rating Maintained Amid Mixed Performance and Revised GuidanceWe learned Enflonsia revenue for the first time on the call ($79M) driven by CDC stockpiling ahead of the RSV season. Gardasil stabilized in the quarter and met consensus, but ACIP one-dose vote risks remains ahead (albeit no scheduled ACIP meeting before year end). Our take: A decent performance this quarter, but nothing meaningfully changing the view on P/E multiple rerating (pipeline / M&A) or path to EPS growth beyond Keytruda patent. Post the quarter announcement, we do praise the Blackstone sac-TMT funding deal, a good option for MRK to manage spend ($700m in 2026) as they head towards pipeline expansion & Keytruda cliff.
Leerink Partners
$107
Buy
6.57%
Upside
Reiterated
10/13/25
J.P. Morgan
$120
Buy
19.52%
Upside
Reiterated
09/16/25
Best Analysts Covering Merck & Company
1 Month
xxx
Success Rate
12/16 ratings generated profit
Average Return
+1.52%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +1.52% per trade.
3 Months
xxx
Success Rate
12/16 ratings generated profit
Average Return
+3.48%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +3.48% per trade.
1 Year
Success Rate
12/16 ratings generated profit
Average Return
+10.42%
reiterated a buy rating 9 days ago
Copying Tim Anderson's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +10.42% per trade.
2 Years
xxx
Success Rate
15/18 ratings generated profit
Average Return
+16.29%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +16.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRK Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
4
3
2
0
0
Buy
24
24
23
15
18
Hold
27
24
17
12
18
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
56
52
42
27
36
Each month's total comprises the sum of three months' worth of ratings.
MRK Financial Forecast
MRK Stock Forecast FAQ
What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 103.73.
What is MRK’s upside potential, based on the analysts’ average price target?
Merck & Company has 3.32% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRK a Buy, Sell or Hold?
Merck & Company has a consensus rating of Moderate Buy which is based on 6 buy ratings, 8 hold ratings and 0 sell ratings.
What is Merck & Company’s price target?
The average price target for Merck & Company is 103.73. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $139.00 ,the lowest forecast is $82.00. The average price target represents 3.32% Increase from the current price of $100.4.
The highest analyst price target is $139.00 ,the lowest forecast is $82.00. The average price target represents 3.32% Increase from the current price of $100.4.
What do analysts say about Merck & Company?
Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of MRK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.